# Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty

> **NCT03234374** · PHASE1 · COMPLETED · sponsor: **Innocoll** · enrollment: 52 (actual)

## Conditions studied

- Hernioplasty

## Interventions

- **COMBINATION_PRODUCT:** INL-001 (bupivacaine HCl collagen implant)
- **DRUG:** Marcaine 0.25% infiltration

## Key facts

- **NCT ID:** NCT03234374
- **Lead sponsor:** Innocoll
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-02
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234374, "Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03234374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*